Datopotamab deruxtecan: a new era in targeted therapy for metastatic breast cancer
{{output}}
Datopotamab deruxtecan (Datroway) is approved by the FDA to treat hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that is metastatic or incurable. This antibody-drug combination consists of a linker, the cytotoxic com... ...
